SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Amphivena Therapeutics, Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell engager for the treatment of Acute Myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback